Ecstasy drug tested for schizophrenia social symptoms
NCT ID NCT05770375
First seen Jun 26, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This early-stage trial is testing whether the drug MDMA (commonly known as ecstasy) is safe and tolerable for people with schizophrenia. The goal is to see if it can help with social withdrawal, a common and hard-to-treat symptom. Twenty stable participants will receive three different doses in order, and researchers will monitor for any worsening of psychotic symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MDMA (a psychoactive drug)
- What this could lead to
- If it works, this could point toward a new treatment for social withdrawal in schizophrenia, a symptom that current medications don't help.
- What could go wrong
- This is a very early, small trial (20 people) just checking safety. It may not work, and MDMA could worsen psychotic symptoms in some people.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCLA
RECRUITINGLos Angeles, California, 90025, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new pill for schizophrenia pass its first human test?
- Can a new daily pill offer safer Long-Term control of schizophrenia?
- Can an Anti-Seizure drug quiet the brain and sharpen thinking in schizophrenia?
- Can a dissolving film tame agitation in schizophrenia?
- Can a phone app teach the brain to read social cues?
- Can a gentle brain current silence voices that medication Can't?